Prophylactic Human Vaccine Market
– Regional Analysis
On the basis of region, the
global Prophylactic
Human Vaccine Market is segmented into North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa.
Geographically, North America is
probable to lead in the global prophylactic human vaccine market, owing to
receiving large number of research grants by government. For instance, in
September 2018, GeoVax Labs, Inc., U.S.-based company recieved grant of US$
2,442,307 by the U.S. Army Medical Research Acquisition Activity. The grant was
awarded as a cooperative agreement for novel Lassa Fever (LF) vaccine
(GEO-LM01) development program. GEO-LM01 uses Modified Vaccinia Ankara (MVA)
and Virus-Like Particle (VLP) vaccine platform that has been demonstrated to be
safe and induce antibody responses in patients. Moreover, MVA-VLP platform has shown
effective results in other cases such as GeoVax’s prophylactic HIV vaccine,
GeoVax’s Ebola (EBOV) vaccine, and GeoVax’s Zika vaccine in its respective
preclinical studies.
Prophylactic human vaccines
stimulate the immune response and are intended for ameliorating the effects of
future infection caused by pathogens in human beings. Novel vaccine development
technologies such as viral-like particles are used in developing Hepatitis B
Virus (HBV) vaccines, and Human Papilloma Virus (HPV) vaccines. For instance,
in March 2014, CureVac AG received EUR 2 million Vaccine Prize from European
Commission for its novel RNActive vaccine technology. This RNActive vaccine
technology enables production of safe, efficacious, and cost-effective vaccines
that are protected against elevated temperature as well as inadvertent
freezing.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2261
Prophylactic Human Vaccine Market
– Drivers
Increasing number of pipeline
studies and rising involvement of key players for vaccine development is expected
to propel growth of the prophylactic human vaccine market during the forecast
period. For instance, in October 2018, CureVac AG, announced to initiate dose
escalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202
is a prophylactic vaccine encoding RABV-G, the rabies virus glycoprotein. This
will enable vaccinated individual's own cells to produce RABV-G protein, by
which immune response gets triggered. This study is estimated to complete in
January 2021.
Moreover, in October 2018,
Valneva SE announced progress in its Phase 1 program targeting a single-shot
vaccine against Chikungunya. It is designed for prophylactic, active,
single-dose immunization against Chikungunya in humans. The vaccine aims for
long-lasting protection and an anticipated safety profile similar to other
approved vaccines for active immunization in adults and children.
Furthermore, rising initiatives
by various scientists to develop innovative solutions to fight against
infectious diseases is expected to drive growth of the market. For instance,
VBI Vaccines Inc., in September 2018, announced formation of three Scientific
and Clinical Advisory Boards (SABs) comprising leading experts in infectious
disease and immuno-oncology research and vaccine development targeting
hepatitis B, Cytomegalovirus (CMV), and Glioblastoma (GBM). This collaboration
is expected to propel growth of the market, owing to enhanced vaccine
development.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/prophylactic-human-vaccine-market-2261
Prophylactic Human Vaccine Market
– Restraint
Significant barriers in the
vaccine development such as virus diversity and limited number of animal models
are estimated to hamper growth of the prophylactic human vaccine market. For
instance, according to Gastroenterology, in October 2018, vaccine development
requires huge investment from various resources and is very challenging.
Designing vaccine trials in human is difficult since following immunization the
chances for develop an acute infection is very high. Therefore, anti-viral
treatment has to be offered immediately, which makes it a challenging task to
manage disease.
Europe region is also expected to
perceive extensive growth in prophylactic human vaccine market, due to rising
initiatives by government for developing efficient and safe vaccines. For
instance, in October 2017, the European Commission funded TRANSVAC, a new
infrastructure project. This project aims to rapidly develop effective vaccines
in order to address European health challenges and in turn increase the
sustainability of EC vaccine projects in Europe. TRANSVAC offers high-quality
technical services to support development of prophylactic and therapeutic
vaccines for both human and animal use.
The key players operating in
prophylactic human vaccine market include, GlaxoSmithKline Plc., Merck &
Co., Inc., Pfizer Inc., Janssen Pharmaceuticals, Inc., Altimmune, Inc., Bharat
Biotech International Limited, Serum Institute of India Pvt. Ltd., Sanofi Pasteur
SA, Shanghai BravoBio Co., Ltd., SK Chemicals Co., Ltd., Takeda Pharmaceutical
Company Limited, BiondVax Pharmaceuticals Ltd., and SK Chemicals Co., Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2261
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment